FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 524 participants.

Also called NCT06409364

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 524 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06409364
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Australia, New Zealand (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06409364. Randomized; quadruple masking; primary purpose treatment. Start 2025-08-13 (actual); primary completion 2029-07-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage
Acronym
FLASH
Condition
Aneurysmal Subarachnoid Hemorrhage
Intervention (Drug)
Fludrocortisone
Intervention (Drug)
Placebo
Lead sponsor
The George Institute (class: other)

Record details

Record id
cardio:ct-nct06409364
Content hash
193e6d37303159cd044f04e1f3b2a0efcad7d5518344cbb233626e0043ebff68